In-process research and development (IPRD) contributed a negative $6.39/share, driven by the Karua asset acquisition and SystImmune collaboration. The company forecasts ~$16B in operating expenses ...

In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ADC from China’s SystImmune in a deal that could swell to $8.4 billion. It gives BMS ...

*GAAP and Non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income. **See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 ...

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront.

One of the notable candidates in this field is BL-B01D1, developed by Systimmune. This EGFRxHER3 bispecific ADC employs a cleavable linker to connect a novel topoisomerase I (TOP-I) inhibitor payload.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The Advisory Committee provides strategic guidance to promote equitable and accessible healthcare. By holding organizations accountable to measurable benchmarks put in place by the Centers for ...

I am so proud of the accomplishment at SystImmune. Two new #ADCs, M11D01 and M7D01, received IND clearance from the U.S. FDA. Thankful for the hard work by the #SystImmune team!